Global H1N1 (swine flu) Vaccination Market
Global H1N1 (swine flu) Vaccination Market

H1N1 (swine flu) Vaccination Comprehensive Study by Treatment type (Influenza, Meningococcal, Cervical cancer, Pneumococcal, Hepatitis, Measles, Mumps, Rubella), End user (Hospital, Clinics) Players and Region - Global Market Outlook to 2024

H1N1 (swine flu) Vaccination Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jan 2019 Edition 218 Pages 167 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global H1N1 (swine flu) Vaccination Market Overview:
Swine flu is a respiratory infection caused by H1N1 virus, also known as swine flu virus. These viruses also infect the respiratory system of pigs causing barking cough, decrease in appetite, nasal secretions, & listless behavior. Influenza viruses can also be transmitted to human beings. Swine flu viruses can encourage genetic changes or mutations so that these are easily transmissible among humans. In April 2009, swine flu outbreak was first detected in Mexico & was caused due to the H1N1 virus. Symptoms of swine flu infection in humans are similar to influenza infection, these include cough, nasal secretions, headache, fatigue, & fever. Some of the key players profiled in the study are Baxter International Inc (United States), Butantan Institute (Brazil), Changchun Institute of Biological Products (China), Crucell N.V. (Netherlands), Csl (Australia), Denka Seiken Co Ltd (Japan), Green Cross Corp (South Korea), Glaxosmithkline Plc (United States), Hualan Biological Engineering Inc (China), Inovio Biomedical Corp (United States), Kitasato Institute (Japan) and Medimmune (United States).

On the basis of geography, the market of H1N1 (swine flu) Vaccination has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the H1N1 (swine flu) Vaccination market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Favorable government initiatives
  • H1N1 virus spreads very quickly and easily

Market Trend
  • Large-Scale Investments Pose Entry Barriers for Smaller Players

Restraints
  • Availability of substitute treatment
  • Limited consumer segments

Opportunities
  • Opportunity for emerging economies
  • Inclination towards cell-based manufacturing

Challenges
  • strong competition with low profit margins
  • Side-effects and safety issues related to vaccine



On April 26, 2009, public health officials from the Centers for Disease Control (CDC) and the U.S. Secretary of Homeland Security held a press conference and declared a national public health emergency. The declaration came in response to identification of a new novel Influenza A (H1N1) “swine flu” virus (combination of swine, bird and human influenza viruses) that was making people sick and causing deaths in Mexico. By June 11, the World Health Organization (WHO) raised the global influenza pandemic alert to the highest Phase 6 level.U.S. Food and Drug Administration (FDA) has approved the use of one dose of vaccine against 2009 H1N1 influenza virus for persons 10 years of age & older. For children who are 6 months through 9 years of age, two doses of the vaccine are recommended. These two doses should be separated by 4 weeks.
The global H1N1 (swine flu) vaccination market is highly fragmented & the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.

Target Audience:
Manufacturer, Raw material supplier, Channel partners, Industry Association, Downstream Vendors, Governments and investment communities, Research organizations and associations and End users (hospitals, clinics)

Major Objectives Focused through this Study
• To define, describe, and forecast the Global H1N1 (swine flu) Vaccination market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the H1N1 (swine flu) Vaccination market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the H1N1 (swine flu) Vaccination industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Merck & Co (United States), Novartis (Switzerland), Novavax (United States) and Omninvest (Switzerland).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the H1N1 (swine flu) Vaccination market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Treatment type
  • Influenza
  • Meningococcal
  • Cervical cancer
  • Pneumococcal
  • Hepatitis
  • Measles
  • Mumps
  • Rubella

By End user
  • Hospital
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Favorable government initiatives
      • 3.2.2. H1N1 virus spreads very quickly and easily
    • 3.3. Market Challenges
      • 3.3.1. Strong competition with low profit margins
      • 3.3.2. Side-effects and safety issues related to vaccine
    • 3.4. Market Trends
      • 3.4.1. Large-Scale Investments Pose Entry Barriers for Smaller Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global H1N1 (swine flu) Vaccination, by Treatment type, End user and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global H1N1 (swine flu) Vaccination (Value)
      • 5.2.1. Global H1N1 (swine flu) Vaccination by: Treatment type (Value)
        • 5.2.1.1. Influenza
        • 5.2.1.2. Meningococcal
        • 5.2.1.3. Cervical cancer
        • 5.2.1.4. Pneumococcal
        • 5.2.1.5. Hepatitis
        • 5.2.1.6. Measles
        • 5.2.1.7. Mumps
        • 5.2.1.8. Rubella
      • 5.2.2. Global H1N1 (swine flu) Vaccination by: End user (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
      • 5.2.3. Global H1N1 (swine flu) Vaccination Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. H1N1 (swine flu) Vaccination: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Baxter International Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Butantan Institute (Brazil)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Changchun Institute of Biological Products (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Crucell N.V. (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Csl (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Denka Seiken Co Ltd (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Green Cross Corp (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glaxosmithkline Plc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hualan Biological Engineering Inc (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Inovio Biomedical Corp (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Kitasato Institute (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Medimmune (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global H1N1 (swine flu) Vaccination Sale, by Treatment type, End user and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global H1N1 (swine flu) Vaccination (Value)
      • 7.2.1. Global H1N1 (swine flu) Vaccination by: Treatment type (Value)
        • 7.2.1.1. Influenza
        • 7.2.1.2. Meningococcal
        • 7.2.1.3. Cervical cancer
        • 7.2.1.4. Pneumococcal
        • 7.2.1.5. Hepatitis
        • 7.2.1.6. Measles
        • 7.2.1.7. Mumps
        • 7.2.1.8. Rubella
      • 7.2.2. Global H1N1 (swine flu) Vaccination by: End user (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
      • 7.2.3. Global H1N1 (swine flu) Vaccination Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. H1N1 (swine flu) Vaccination: by Treatment type(USD Million)
  • Table 2. H1N1 (swine flu) Vaccination Influenza , by Region USD Million (2013-2018)
  • Table 3. H1N1 (swine flu) Vaccination Meningococcal , by Region USD Million (2013-2018)
  • Table 4. H1N1 (swine flu) Vaccination Cervical cancer , by Region USD Million (2013-2018)
  • Table 5. H1N1 (swine flu) Vaccination Pneumococcal , by Region USD Million (2013-2018)
  • Table 6. H1N1 (swine flu) Vaccination Hepatitis , by Region USD Million (2013-2018)
  • Table 7. H1N1 (swine flu) Vaccination Measles , by Region USD Million (2013-2018)
  • Table 8. H1N1 (swine flu) Vaccination Mumps , by Region USD Million (2013-2018)
  • Table 9. H1N1 (swine flu) Vaccination Rubella , by Region USD Million (2013-2018)
  • Table 10. H1N1 (swine flu) Vaccination: by End user(USD Million)
  • Table 11. H1N1 (swine flu) Vaccination Hospital , by Region USD Million (2013-2018)
  • Table 12. H1N1 (swine flu) Vaccination Clinics , by Region USD Million (2013-2018)
  • Table 13. South America H1N1 (swine flu) Vaccination, by Country USD Million (2013-2018)
  • Table 14. South America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 15. South America H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 16. Brazil H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 17. Brazil H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 18. Argentina H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 19. Argentina H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 20. Rest of South America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 21. Rest of South America H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 22. Asia Pacific H1N1 (swine flu) Vaccination, by Country USD Million (2013-2018)
  • Table 23. Asia Pacific H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 24. Asia Pacific H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 25. China H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 26. China H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 27. Japan H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 28. Japan H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 29. India H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 30. India H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 31. South Korea H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 32. South Korea H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 33. Taiwan H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 34. Taiwan H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 35. Australia H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 36. Australia H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 37. Rest of Asia-Pacific H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 38. Rest of Asia-Pacific H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 39. Europe H1N1 (swine flu) Vaccination, by Country USD Million (2013-2018)
  • Table 40. Europe H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 41. Europe H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 42. Germany H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 43. Germany H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 44. France H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 45. France H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 46. Italy H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 47. Italy H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 48. United Kingdom H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 49. United Kingdom H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 50. Netherlands H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 51. Netherlands H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 52. Rest of Europe H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 53. Rest of Europe H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 54. MEA H1N1 (swine flu) Vaccination, by Country USD Million (2013-2018)
  • Table 55. MEA H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 56. MEA H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 57. Middle East H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 58. Middle East H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 59. Africa H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 60. Africa H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 61. North America H1N1 (swine flu) Vaccination, by Country USD Million (2013-2018)
  • Table 62. North America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 63. North America H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 64. United States H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 65. United States H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 66. Canada H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 67. Canada H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 68. Mexico H1N1 (swine flu) Vaccination, by Treatment type USD Million (2013-2018)
  • Table 69. Mexico H1N1 (swine flu) Vaccination, by End user USD Million (2013-2018)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. H1N1 (swine flu) Vaccination: by Treatment type(USD Million)
  • Table 83. H1N1 (swine flu) Vaccination Influenza , by Region USD Million (2019-2024)
  • Table 84. H1N1 (swine flu) Vaccination Meningococcal , by Region USD Million (2019-2024)
  • Table 85. H1N1 (swine flu) Vaccination Cervical cancer , by Region USD Million (2019-2024)
  • Table 86. H1N1 (swine flu) Vaccination Pneumococcal , by Region USD Million (2019-2024)
  • Table 87. H1N1 (swine flu) Vaccination Hepatitis , by Region USD Million (2019-2024)
  • Table 88. H1N1 (swine flu) Vaccination Measles , by Region USD Million (2019-2024)
  • Table 89. H1N1 (swine flu) Vaccination Mumps , by Region USD Million (2019-2024)
  • Table 90. H1N1 (swine flu) Vaccination Rubella , by Region USD Million (2019-2024)
  • Table 91. H1N1 (swine flu) Vaccination: by End user(USD Million)
  • Table 92. H1N1 (swine flu) Vaccination Hospital , by Region USD Million (2019-2024)
  • Table 93. H1N1 (swine flu) Vaccination Clinics , by Region USD Million (2019-2024)
  • Table 94. South America H1N1 (swine flu) Vaccination, by Country USD Million (2019-2024)
  • Table 95. South America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 96. South America H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 97. Brazil H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 98. Brazil H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 99. Argentina H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 100. Argentina H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 101. Rest of South America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 102. Rest of South America H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 103. Asia Pacific H1N1 (swine flu) Vaccination, by Country USD Million (2019-2024)
  • Table 104. Asia Pacific H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 105. Asia Pacific H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 106. China H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 107. China H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 108. Japan H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 109. Japan H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 110. India H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 111. India H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 112. South Korea H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 113. South Korea H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 114. Taiwan H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 115. Taiwan H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 116. Australia H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 117. Australia H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 118. Rest of Asia-Pacific H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 119. Rest of Asia-Pacific H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 120. Europe H1N1 (swine flu) Vaccination, by Country USD Million (2019-2024)
  • Table 121. Europe H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 122. Europe H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 123. Germany H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 124. Germany H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 125. France H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 126. France H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 127. Italy H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 128. Italy H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 129. United Kingdom H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 130. United Kingdom H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 131. Netherlands H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 132. Netherlands H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 133. Rest of Europe H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 134. Rest of Europe H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 135. MEA H1N1 (swine flu) Vaccination, by Country USD Million (2019-2024)
  • Table 136. MEA H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 137. MEA H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 138. Middle East H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 139. Middle East H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 140. Africa H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 141. Africa H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 142. North America H1N1 (swine flu) Vaccination, by Country USD Million (2019-2024)
  • Table 143. North America H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 144. North America H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 145. United States H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 146. United States H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 147. Canada H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 148. Canada H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 149. Mexico H1N1 (swine flu) Vaccination, by Treatment type USD Million (2019-2024)
  • Table 150. Mexico H1N1 (swine flu) Vaccination, by End user USD Million (2019-2024)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global H1N1 (swine flu) Vaccination: by Treatment type USD Million (2013-2018)
  • Figure 5. Global H1N1 (swine flu) Vaccination: by End user USD Million (2013-2018)
  • Figure 6. South America H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 7. Asia Pacific H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 8. Europe H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 9. MEA H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 10. North America H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 11. Global H1N1 (swine flu) Vaccination share by Players 2018 (%)
  • Figure 12. Global H1N1 (swine flu) Vaccination share by Players (Top 3) 2018(%)
  • Figure 13. Global H1N1 (swine flu) Vaccination share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Baxter International Inc (United States) Revenue, Net Income and Gross profit
  • Figure 16. Baxter International Inc (United States) Revenue: by Geography 2018
  • Figure 17. Butantan Institute (Brazil) Revenue, Net Income and Gross profit
  • Figure 18. Butantan Institute (Brazil) Revenue: by Geography 2018
  • Figure 19. Changchun Institute of Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 20. Changchun Institute of Biological Products (China) Revenue: by Geography 2018
  • Figure 21. Crucell N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Crucell N.V. (Netherlands) Revenue: by Geography 2018
  • Figure 23. Csl (Australia) Revenue, Net Income and Gross profit
  • Figure 24. Csl (Australia) Revenue: by Geography 2018
  • Figure 25. Denka Seiken Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Denka Seiken Co Ltd (Japan) Revenue: by Geography 2018
  • Figure 27. Green Cross Corp (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. Green Cross Corp (South Korea) Revenue: by Geography 2018
  • Figure 29. Glaxosmithkline Plc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Glaxosmithkline Plc (United States) Revenue: by Geography 2018
  • Figure 31. Hualan Biological Engineering Inc (China) Revenue, Net Income and Gross profit
  • Figure 32. Hualan Biological Engineering Inc (China) Revenue: by Geography 2018
  • Figure 33. Inovio Biomedical Corp (United States) Revenue, Net Income and Gross profit
  • Figure 34. Inovio Biomedical Corp (United States) Revenue: by Geography 2018
  • Figure 35. Kitasato Institute (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Kitasato Institute (Japan) Revenue: by Geography 2018
  • Figure 37. Medimmune (United States) Revenue, Net Income and Gross profit
  • Figure 38. Medimmune (United States) Revenue: by Geography 2018
  • Figure 39. Global H1N1 (swine flu) Vaccination: by Treatment type USD Million (2013-2018)
  • Figure 40. Global H1N1 (swine flu) Vaccination: by End user USD Million (2013-2018)
  • Figure 41. South America H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 42. Asia Pacific H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 43. Europe H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 44. MEA H1N1 (swine flu) Vaccination Share (%), by Country
  • Figure 45. North America H1N1 (swine flu) Vaccination Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Baxter International Inc (United States)
  • Butantan Institute (Brazil)
  • Changchun Institute of Biological Products (China)
  • Crucell N.V. (Netherlands)
  • Csl (Australia)
  • Denka Seiken Co Ltd (Japan)
  • Green Cross Corp (South Korea)
  • Glaxosmithkline Plc (United States)
  • Hualan Biological Engineering Inc (China)
  • Inovio Biomedical Corp (United States)
  • Kitasato Institute (Japan)
  • Medimmune (United States)
Additional players considered in the study are as follows:
Merck & Co (United States) , Novartis (Switzerland) , Novavax (United States) , Omninvest (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Protein Expression Comprehensive Study by Application (Therapeutic, Research, Industrial), Systems Type (Prokaryotic Expression Systems {Escherichia coli (E. coli) Systems and Other Systems}, Mammali...
Protein Expression Comprehensive Study by Application (Therapeutic, Research, Industrial), Systems Type (Prokaryotic Expression Systems {Escherichia coli (E. coli) Systems and Other Systems}, Mammali...
$ 3800
Regenerative Medicine Comprehensive Study by Type (Cell-Based, Acellular), Application (Cardiovascular, Oncology, Dermatology, Wound Healing, Neurology, Others), Technology (Stem Cell Therapy, Platel...
Regenerative Medicine Comprehensive Study by Type (Cell-Based, Acellular), Application (Cardiovascular, Oncology, Dermatology, Wound Healing, Neurology, Others), Technology (Stem Cell Therapy, Platel...
$ 3800
Hyaluronic Acid Comprehensive Study by Type (Single-Injection, Three-Injection Cycle, Five-Injection Cycle), Application (Anti-Aging Treatments, Nutritional Supplements, Medical Treatments, Others), ...
Hyaluronic Acid Comprehensive Study by Type (Single-Injection, Three-Injection Cycle, Five-Injection Cycle), Application (Anti-Aging Treatments, Nutritional Supplements, Medical Treatments, Others), ...
$ 3800
Fluconazole Comprehensive Study by Distribution Channel (Offline (Hospital, Retail Pharmacy), Online Pharmacy), Form Type (Injectable, Powder, Tablet) Players and Region - Global Market Outlook to 20...
Fluconazole Comprehensive Study by Distribution Channel (Offline (Hospital, Retail Pharmacy), Online Pharmacy), Form Type (Injectable, Powder, Tablet) Players and Region - Global Market Outlook to 20...
$ 3800
Injectable Drug Delivery Comprehensive Study by Type (Devices, Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable ...
Injectable Drug Delivery Comprehensive Study by Type (Devices, Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable ...
$ 3800
Lignocaine Comprehensive Study by Application (Local Anesthesia, Dentistry, Cardiac Arrhythmia, Epilepsy, Cosmetics, Anti-Arrhythmic, Others), Formulations (Injections, Creams, Ointments, Gels, Aeros...
Lignocaine Comprehensive Study by Application (Local Anesthesia, Dentistry, Cardiac Arrhythmia, Epilepsy, Cosmetics, Anti-Arrhythmic, Others), Formulations (Injections, Creams, Ointments, Gels, Aeros...
$ 3800